PBPK Modeling Approach for Predictions of Human CNS Drug Brain Distribution

Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs

Volumn , Issue , 2015, Pages 296-323

  De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Central nervous system (CNS); Human CNS drug brain distribution; PBPK modeling approach; Physiologically based pharmacokinetic model (PBPK)

Indexed keywords

NEUROPHYSIOLOGY; PHARMACOKINETICS;

CENTRAL NERVOUS SYSTEMS; DRUG TARGETS; HUMAN CNS DRUG BRAIN DISTRIBUTION; MODEL APPROACH; PHYSIOLOGICAL PROCESS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS; PREDICTIVE POWER; SYSTEM PROPERTY;

PHYSIOLOGICAL MODELS;

EID: 85017367333     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118788523.ch14     Document Type: Chapter

References (139)

1. Hammarlund-Udenaes M, Friden M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res 2008;25:1737-1750.
2. Abbott NJ, Dolman DE, Patabendige AK. Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 2008 Nov;9(9):901-910.
3. Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 2007;35:1711-1719.
4. Loryan I, Friden M, Hammarlund-Udenaes M. The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS 2013 Jan 21;10(1):6.
5. Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med 1985;26:72-76.
6. Frank H, Gray SJ. The determination of plasma volume in man with radioactive chromic chloride. J Clin Invest 1953;32:991-999.
7. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Childhood 1973;48:757.
8. Harashima H, Sawada Y, Sugiyama Y, Iga T, Hanano M. Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J Pharmacokin Biopharm 1985;13:425-550.
9. Sandor P, Cox-van Put J, de Jong W, de Wied D. Continuous measurement of cerebral blood volume in rats with the photoelectric technique: effect of morphine and naloxone. Life Sci 1986 Nov 3;39(18):1657-1665.
10. Forster A, Juge O, Morel D. Effects of midazolam on cerebral blood flow in human volunteers. Anesthesiology 1982 Jun;56(6):453-455.
11. Ito H, Inoue K, Goto R, Kinomura S, Taki Y, Okada K, Sato K, Sato T, Kanno I, Fukuda H. Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry. Ann Nucl Med 2006;20:131-138.
12. Cserr HF. Potassium exchange between cerebrospinal fluid, plasma, and brain. Am J Physiol 1965;209:1219-1226.
13. Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol 1981;240:F319-F328.
14. Dekaban AS, Sadowsky D. Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights. Ann Neurol 1978;4:345-356.
15. Thorne RG, Hrabetova S, Nicholson C. Diffusion of epidermal growth factor in rat brain extra-cellular space measured by integrative optical imaging. J Neurophysiol 2004;92:3471-3481.
16. Abbott NJ. Evidence of bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 2004;45:545-552.
17. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 2005 Feb;25(1):5-23.
18. Kimelberg HK. Water homeostasis in the brain: basic concepts. Neuroscience 2004;129: 851-760.
19. Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol 1992;262:R20-R24.
20. Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008;14:5-10.
21. Bass NH, Lundborg P. Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-(14C)inulin after intrathecal infusion. Brain Res 1973;30:52:323-332.
22. Oldendorf WH. Cerebrospinal fluid formation and circulation. Prog Nucl Med 1972;1: 336-358.
23. Condon P, Patterson J, Wyper D, Hadley D, Grant R, Teasdale G. Use of magnetic resonance imaging to measure intracranial cerebrospinal fluid volume. Lancet 1986;327: 1355-1357.
24. Kohn MI, Tanna NK, Herman GT, Resnick SM, Mozley PD, Gur RE, Alavi A, Zimmerman RA, Gur RC. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 1991;178:115-122.
25. Dickey CC, Shenton ME, Hirayasu Y, Fischer I, Voglmaier MM, Niznikiewicz MA, Seidman LJ, Fraone S, McCarley RW. Large CSF volume not attributable to ventricular volume in schizotypical personality disorder. Am J Psychiatry 2000;157:48-54.
26. Adam R, Greenberg JO. The mega cisterna magna. J Neurosurg 1978;48:190-192.
27. Robertson EG. Developmental defects of the cisterna magna and dura mater. J Neurol Neurosurg Psychiatry 1949;12:39-51.
28. Levinger IM. The cerebral ventricles of the rat. J Anat 1971;108:447-451.
29. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011;8:7.
30. Bradbury MW. The Concept of a Blood-Brain Barrier. Chichester: Wiley; 1979.
31. Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res 1990 Oct 1;56(1):47-53.
32. Crone C, Christensen O. Electrical resistance of a capillary endothelium. J Gen Physiol 1981;77:349-371.
33. Dohrmann GJ. The choroid plexus: a historical review. Brain Res 1970;18:197-218.
34. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 1999;27:827-834.
35. Karssen AM, Meijer OC, van der Sandt ICJ, Lucassen P J, de Lange ECM, de Boer AG, de Kloet ER. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001;142:2686-2694.
36. Kooij G, van Horssen J, de Lange EC, Reijerkerk A, van der Pol SM, van Het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun. 2010; 34(4):416-425.
37. De Lange ECM, Ravenstijn PGM, Groenendaal D, van Steeg TS. Toward the prediction of CNS drug effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 2005;7:article 54.
38. Mulder M, Blokland A, van den Berg DJ, Schulten H, Bakker AH, Terwel D, Honig W, de Kloet ER, Havekes LM, Steinbusch HW, de Lange EC. Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest 2001;81(7):953-960.
39. Danhof M, de Jongh J, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47: 357-400.
40. Ravenstijn PG, Merlini M, Hameetman M, Murray TK, Ward MA, Lewis H, Ball G, Mottart C, de Ville de Goyet C, Lemarchand T, van Belle K, O'Neill MJ, Danhof M, De Lange EC. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PKPD experiments. J Pharmacol Toxicol Methods 2007;57(2):114-130.
41. Ravenstijn PGM, Drenth H, Baatje MS, O'Neill MJ, Danhof M, de Lange ECM. Evaluation of BBB transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease. Fluids Barriers CNS 2012;9:4.
42. Syvänen S, Lindhe Ö, Palner M, Kornum BR, Rahman O, Längström B, Knudsen GM, Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009;37:635-643.
43. Westerhout J, Danhof M, de Lange EC. Preclinical prediction of human brain target site concentrations: Considerations in extrapolating to the clinical setting. J Pharm Sci 2011; 100(9):3577-3593.
44. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange ECM. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 2012;14(3):543-553.
45. De Lange ECM. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 2013b;10:12.
46. Stevens J, Ploeger B, Hammarlund-Udenaes M, Osswald G, vd Graaf PH, Danhof M, de Lange ECM. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokin Pharmacodyn 2012;39(5):463-477.
47. Segal MB. Extracellular and cerebrospinal fluids. J Inher Metab Dispos 1993;16:617-638.
48. Cserr HF. Convection of brain interstitial fluid. In: Shapiro K, Marmarou A, Portnoy H, eds. Hydrocephalus. New York: Raven Press; 1984:59-68.
49. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
50. Bernacki J, Dobrowolska A, Nierwinska K, Malecki, A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008;60:600-622.
51. Del Bigio MR. The ependyma: a protective barrier between brain and cerebrospinal fluid. Glia 1995;14:1-13.
52. Crone C, Olesen SP. Electrical resistance of a brain microvascular endothelium. Brain Res 1982;241:49-55.
53. Smith QR, Rapoport SI. Cerebrovascular permeability coefficients to sodium, potassium, and chloride. J Neurochem 1986;46(6):1732-1742.
54. Pardridge WM. Peptide Drug Delivery to the Brain. New York: Raven Press; 1991.
55. Duvernoy H, Delon S, Vannson JL. The vascularization of the human cerebellar cortex. Brain Res Bull 1983;11:419-480.
56. De Lange EC. Potential role of ABC transporters as a detoxification system at the blood-cerebrospinal fluid-barrier. Adv Drug Del Rev 2004;56(12);1793-1809.
57. Ghersi-Egea JF, Strazielle N, Murat A, Jouvet A, Buénerd A, Belin MF. Brain protection at the blood-cerebrospinal fluid interface involves a glutathione-dependent metabolic barrier mechanism. J Cereb Blood Flow Metab 2006;26(9):1165-1175.
58. Ghersi-Egea JF, Monkkonen KS, Schmitt C, Honnorat J, Fèvre-Montange M, Strazielle N. Blood-brain interfaces and cerebral drug bioavailability. Rev Neurol (Paris) 2009; 165(12):1029-1038.
59. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 2011 Jan 18;8(1):3.
60. Davson H, Segal MB. Physiology of the CSF and Blood-Brain Barriers. Boca Raton: CRC Press; 1996.
61. Davson H. The cerebrospinal fluid. Handbook Neurochem 1969;2:23-48.
62. Keep RF, Jones HC. Cortical microvessels during brain development: a morphometric study in the rat. Microvasc Res 1990a;40:412-426.
63. Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependymal in the rat. Dev Brain Res 1990b;56:47-53.
64. Johanson CE, Stopa EG, McMillan PN. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol Biol 2011;686:101-131.
65. Betz AL, Firtha JA, Goldstein GW. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res 1980;192(1):17-28.
66. Tayarani I, Cloez I, Clément M, Bourre JM. Antioxidant enzymes and related trace elements in aging brain capillaries and choroid plexus. J Neurochem 1989;53:817-824.
67. Fukushima H, Fujimoto M, Ide M. Quantitative detection of blood-brain barrier-associated enzymes in cultured endothelial cells of procine brain microvessels. J In Vitro Cell Dev Biol 1990;26(6):612-620.
68. Volk B, Hettmansperger U, Papp TH, Amelizad Z, Oesch F, Knoth R. Mapping of phenytoin-inducible cytochrome P450 immunoreactivity in the mouse central nervous system. Neuroscience 1991;42:215-235.
69. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res 1991;16:65-82.
70. Strazielle N, Ghersi-Egea JF. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 2013 May 6;10(5): 1473-1491.
71. Banks WA, Kastin AJ. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 1996;59(23):1923-1943.
72. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010 Jan;37(1):13-25.
73. De Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn 2013a;40(3):315-326.
74. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 2010 Mar;99(3):1107-1122.
75. Fenstermacher JD, Patlak CS, Blasberg RG. Transport of material between brain extracellular fluid, brain cells and blood. Fed Proc 1974;33:2070-2074.
76. Spector R, Spector AZ, Snodgrass SR. Model for transport in the central nervous system. Am J Physiol 1977;1:R73-R79.
77. Fenstermacher JD, Wei L, Acuff V, Lin SZ, Chen JL, Bereczki D, Otsuka T, Nakata H, Tajima A, Hans FJ, Ghersi-Egea JF, Finnegan W, Richardson G, Haspel H, Patlak C. The dependency of influx across the blood-brain barrier on blood flow and the apparent flow-independence of glucose influx during stress. In: Greenwood, Begley, Segal, eds. New Concepts of a Blood-Brain Barrier; Plenum, NY, 1995:89-101.
78. Oldendorf WH. Lipid solubility and drug penetration of the blood-brain barrier. Proc Exp Biol Med 1974;14:813-816.
79. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980;23:682-684.
80. De Boer AG, van der Sandt I, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003;43:629-656.
81. Kusuhara H, Sugiyama Y. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Del Rev 2004;56:1741-1763.
82. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005;2:73-85.
83. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; Importance for CNS drug discovery and development. Pharm Res 2007;24(9):1745-1758.
84. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117(2):333-345.
85. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacopro-teomics (PPx): reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 2012;339(2): 579-588.
86. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L. Emerging transporters of clinical importance: an update from the international transporter consortium. Clin Pharmacol Ther 2013;94:52-63.
87. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A. International transporter consortium. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther 2013 Jul;94(1):64-79.
88. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. Disruption of the Mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
89. Borst P, Evers R, Kool M, Wijnholds. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302.
90. Nishino J, Suzuki H, Sugiyama D, Kitazawa T, Ito K, Hanano M, Sugiyama Y. Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein. J Pharmacol Exp Ther 1999;290(1):289-294.
91. Wijnholds J, de Lange ECM, Scheffer GL, van den Berg D-J, Mol CAAM, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000;105:279-285.
92. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001;53:569-596.
93. Scism JL, Powers KM, Artru AA, Lewis L, Shen DD. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res 2000 Nov 24;884(1-2):77-86.
94. Zlokovic BV, Skundric DS, Segal MB, Colover J, Jankov RM, Pejnovic N, Lackovic V, Mackic J, Lipovac MN, Davson H. Blood-brain barrier permeability changes during acute allergic encephalomyelitis induced in the guinea pig. Metab Brain Dispos 1989; 4(1):33-40.
95. Oztaş B, Küçük M. Influence of acute arterial hypertension on blood-brain barrier permeability in streptozocin-induced diabetic rats. Neurosci Lett 1995;188(1):53-56.
96. Ozta§ B, Akgül S, Arslan FB. Influence of surgical pain stress on the blood-brain barrier permeability in rats. Life Sci 2004;74(16):1973-1979.
97. Oztas B, Akgul S, Seker FB. Gender difference in the influence of antioxidants on the blood-brain barrier permeability during pentylenetetrazol-induced seizures in hyperthermic rat pups. Biol Trace Elem Res 2007;118(1):77-83.
98. Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordström CH, Hammarlund-Udenaes M. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol 2004;57(4):427-435.
99. Langford D, Grigorian A, Hurford R, Adame A, Ellis RJ, Hansen L, Masliah E. Altered P-gp expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004;63:1038-1047.
100. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009;118(1):103-113.
101. Bengtsson J, Ederoth P, Ley D, Hansson S, Amer-Wáhlin I, Hellström-Westas L, Marsál K, Nordström CH, Hammarlund-Udenaes M. The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. Br J Pharmacol 2009;157(6):1085-1096.
102. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med 2010;16(12): 1370-1371.
103. Dedrick RL, Bisschoff KB. Species similarities in pharmacokinetics. Fed Proc 1980; 39:54-59.
104. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
105. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, Jacob A, Chassoux F, Daumas-Duport C, Couraud PO, Terasaki T, Scherrmann JM. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011 Aug 1;8(4):1332-1341.
106. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73.
107. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. Receptor occupancy and brain free fraction. Drug Metab Dispos 2009;37: 753-760.
108. Hammarlund-Udenaes M. Active-site concentrations of chemicals-are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 2009;106:215-220.
109. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JPN, Hosea J, Liu, Nelson FR, Szewc MA, Van Deusen J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2005;313:1254-1262.
110. Collins JM, Dedrick LD. Distributed model for drug delivery to CSF and brain tissue. J Am Physiol 1983;14:R303-R310.
111. Colburn WA. Physiologic pharmacokinetic modeling. J Clin Pharmacol 1988;28: 673-677.
112. Espié P, Tytgat D, Sargentini-Maier M-L, Poggesi I, Watelet J-P. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 2009;41:391-407.
113. Ings RMJ. Interspecies scaling and comparisons in drug development and toxicogenetics. Xenobiotica 1990;20:1201-1231.
114. Mayer S, Maickel RP, Brodie BB. Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. J Pharmacol Exp Ther 1959;127: 205-211.
115. Ooie T, Suzuki H, Terasaki T and Sugiyama Y. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J Pharmacol Exp Ther 1997;283:293-304.
116. Wang YF, Welty DF. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm Res 1996;13:398-403.
117. Proescholdt MG, Hutto B, Brady LS, Herkenham M. Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neurosci 2000;95:577-592.
118. Lindberger M, Tomson T, Wallstedt L, Stahle L. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans" a microdialysis study. Epilepsia 2001;42:256-261.
119. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding of CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002;23:327-338.
120. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 2008;25:1469-1483.
121. Maurer TS, DeBartolo DB, Tess DA, Scott D. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005;33:175-181.
122. Vladic A, Klarica M, Bulat M. Dynamics of distribution of 3H-inulin between the cerebrospinal fluid compartments. Brain Res 2009;1248:127-135.
123. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 2009;37:787-793.
124. Ball K, Bouzom F, Scherrmann JM, Walther B, Decleves X. Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier-towards a mechanistic IVIVE-based approach. AAPS J 2013;15(4):913-932.
125. Kielbasa W, Stratford RE Jr. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos 2012 May;40(5):877-883.
126. Kielbasa W, Kalvass JC, Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos 2009;37(1):137-142.
127. Westerhout J, Smeets J, Danhof M, de Lange ECM. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn 2013;40:327-342.
128. Westerhout J, van den Berg DJ, Hartman R, Danhof M, de Lange ECM. Prediction of methotrexate CNS distribution in different species and the influence of disease conditions. Eur J Pharmacol Sci 2014;57:11-24.
129. De Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703.
130. Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 2008;9:46-59.
131. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004;56:1825-1857.
132. Bannwarth B, Netter P, Lapicque F, Gillet P, Pere P, Boccard E, Royer RJ, Gaucher A. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol 1992;34:79-81.
133. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 2009;91:51-58.
134. De Lange ECM, Hesselink MB, Danhof M, De Boer AG, Breimer DD. The use of intra-cerebral microdialysis to determine changes in blood-brain barrier transport characteristics. Pharm Res 1995;12:129-133.
135. Henderson ES, Adamson RH, Denham C, Oliverio VT. The metabolic fate of tritiated methotrexate I. absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer Res 1965;25:1008-1017.
136. Hendel J, Brodthagen H. Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur J Clin Pharmacol 1984;26:103-107.
137. Glantz MJ, Cole BF, Recht L, Akerley W, Milles P, Saris S, Hochberg F, Calabresi P, Egorin MJ. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16: 1561-1567.
138. Reiber H. Flow rate of cerebrospinal fluid (CSF)-α concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994 Apr,122(2):189-203.
139. De Lange ECM. Pharmacometrics in psychiatric diseases. In: Schmidt S, Derendorf H, eds. Applied Pharmacometrics. Springer, New York; 2014.